EZH2 inhibitors for treating lymphoma
US11202781B2 · kind B2 · utility
7Cited by
12References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jan 17, 2019 |
| Grant date | Dec 21, 2021 |
| Priority date | — |
| Expiry date | Oct 13, 2039 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/57407
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, particularly anticancer agents such as prednisone, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.